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Post-admission hematoma expansion in patients with intracerebral hemorrhage (ICH) com-
prises a simultaneous major clinical problem and a possible target for medical intervention.
In any case, the ability to predict and observe hematoma expansion is of great clinical
importance. We review radiological concepts in predicting and observing post-admission
hematoma expansion. Hematoma expansion can be observed within the first 24 h after
symptom onset, but predominantly occurs in the early hours. Thus capturing markers of
on-going bleeding on imaging techniques could predict hematoma expansion.The spot sign
observed on computed tomography angiography is believed to represent on-going bleeding
and is to date the most well investigated and reliable radiological predictor of hematoma
expansion as well as functional outcome and mortality. On non-contrast CT, the presence
of foci of hypoattenuation within the hematoma along with the hematoma-size is reported
to be predictive of hematoma expansion and outcome. Because patients tend to arrive
earlier to the hospital, a larger fraction of acute ICH-patients must be expected to undergo
hematoma expansion. This renders observation and radiological follow-up investigations
increasingly relevant.Transcranial duplex sonography has in recent years proven to be able
to estimate hematoma volume with good precision and could be a valuable tool in bedside
serial observation of acute ICH-patients. Future studies will elucidate, if better prediction
and observation of post-admission hematoma expansion can help select patients, who will
benefit from hemostatic treatment.
Keywords: intracranial hemorrhage, cerebral hemorrhage, cerebral angiography, X-ray computed tomography,
transcranial ultrasonography
BACKGROUND
Early intervention is today a growing concept in the treatment
of stroke patients. Patients arrive in the hospital early after the
onset of stroke symptoms as a consequence of treatment options
in ischemic stroke. Due to the ultra-early work-up, patients with
intracerebral hemorrhages (ICH) will often be diagnosed quickly
after symptom onset. ICH presents in general as devastating
strokes, and patients are often prone to poor outcome. This is
due to the stroke per se and the lack of treatment concepts proven
to be effective in randomized clinical trials. Recently, both surgical
intervention (1) and hemostatic therapy (2) have failed to improve
the functional outcome.
As ICH is diagnosed increasingly early, post-admission hema-
toma expansion will become a more frequent observation. Post-
admission hematoma expansion contributes to the clinical insta-
bility of the patients, but at the same time it might be a promising
target for interventions to limit final hematoma volume, save
brain tissue – and improve functional outcome. Thus, being able
to predict and dynamically observe post-admission hematoma
expansion is of paramount clinical importance. In recent years,
several radiological concepts to predict post-admission hematoma
expansion have been identified. In this review, we summarize radi-
ological predictors of hematoma expansion in patients with ICH.
We further review new imaging concepts in dynamical observation
of post-admission hematoma expansion.
POST-ADMISSION HEMATOMA EXPANSION
Post-admission hematoma expansion is defined as enlargement
of the hematoma volume between the admission imaging pro-
cedure and a later imaging procedure. A variety of definitions
of significant hematoma expansion have been proposed based
on both relative (e.g., 33%) and absolute (e.g., 6 or 12.5 mL)
hematoma volume increase. No convincing evidence exists as to
which of these definitions best discriminate patients prone to poor
functional outcome and all definitions yield equally low sensitiv-
ity (3). However, a trend might exist toward definitions based
on absolute expansion being slightly more clinically meaningful
in terms of outcome compared to definitions based on relative
expansion (3).
Studies to determine the time interval of which post-admission
hematoma expansion occur have been limited by the fact that ser-
ial radiological examinations in order to estimate the hematoma
volume are hard to perform in an unstable patient-group and
would potentially expose the patients to unacceptable amounts
of ionizing radiation. Consequently, most published studies are
limited by few prospective measurements or imprecise retrospec-
tive methodology. Studies indicate that post-admission hematoma
expansion can be observed in up to 40% of patients admitted
in an acute fashion (3). In a prospective study conducted on
patients admitted within 3 h after symptom onset Brott et al.
reported that 26% suffered hematoma expansion within the first
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hour after admission and additional 12% suffered expansion
within the following 23 h (4). Ovesen et al. reported in another
prospective study that active expansion could be observed within
the first 8 h after symptom onset in the group of patients, who
on 24 h follow-up CT-scan presented a final clinically relevant
hematoma expansion (>12.5 mL) (5). Even though the vast major-
ity of the hematoma expansion is observed to occur in the first
hours after stroke onset, evidence also indicates that it is pos-
sible for hematoma expansion to take place later on and up to
24 h (6, 7). This supports the hypothesis that hematoma expan-
sion (Figure 1) is a dynamic process with intermitting bleeding
episodes caused by not only the originally ruptured vessel, but
also by secondary rupture of adjacent vessels exposed to pres-
sure and ischemia inflicted by the hematoma mass-effect (8).
The secondary vessel rupture in the rim of the hematoma might
explain that hematoma expansion does not happen symmetrically
around the surface of the hematoma, but is located non-uniformly
(9). Further, the secondary vessel rupture and intermitting bleed-
ing episodes might also be the cause of the apparent plateau-
phases with constant hematoma volume between active expansion
episodes (5).
Post-admission hematoma expansion has been independently
associated with early neurological deterioration (4, 10), poor
functional outcome, and mortality (11, 12). An almost linear
association between hematoma expansion and the probability of
poor outcome has been reported – with 1 mL additional expansion
yielding a 5% increased risk of death and dependency (12).
FIGURE 1 | Suggested schematic model for a step-wise hematoma
expansion-profile in intracerebral hemorrhages. Phase 1 represents the
initial active bleeding-period most likely caused by the originally ruptured
vessel. If patients are admitted within this phase an active hemorrhage will
still be occurring post-admission and instant expansion can be observed.
After phase 1 a plateau-phase might exist in which the hematoma volume is
constant or active bleeding occurs slowly. In some patients, this phase
might represent the final hematoma volume (horizontal stippled line). Phase
2 represents a secondary bleeding-period. This is likely due to secondary
vessel rupture caused by pressure and ischemia on adjacent tissue
structures or by re-bleeding from the originally ruptured vessel. Some
patients might have multiple secondary bleeding-periods and some even
late (phase 3). Between these periods are interpolated plateau-phases with
relative constant hematoma volume or slow active bleeding. This results in
the final hematoma volume observed on follow-up imaging.
COMPUTED TOMOGRAPHY ANGIOGRAPHY
Post-admission hematoma expansion occurs due to leakage of
blood into an existing hematoma cavity. As previously discussed,
this process represents an on-going or intermittingly on-going
active bleeding process. Consequently, the ability to visual-
ize this process of on-going bleeding could provide us with
excellent prediction of hematoma expansion. It is an alluring
thought that this active bleeding process could be visualized using
radiographic contrast-agents, because leakage from surround-
ing vessels would be represented by pooling of contrast-material
inside the hematoma. The concept of contrast-leakage into the
hematoma in acute ICH-patients undergoing angiography dates
back more than 40 years (13). It was originally observed that
patients arriving earlier in the hospital more often demonstrated
contrast-leakage. In recent years, much attention has been placed
on the possibility of visualizing contrast-leakage using computed
tomography angiography (CTA).
CONTRAST-LEAKAGE ON CT-IMAGING
Traditionally, two interrelated marker of contrast-leakage have
been defined: the spot sign on CTA source images or max-
imum intensity projections and pooling of contrast (contrast
extravasation) in the hematoma (Figure 2).
One of the first studies on contrast extravasation in patients
with spontaneous ICH using CTA was presented by Murai et al.
(14) in 1999. The study looked at extravasation of contrast on
3D-CTA images and concluded that extravasation was linked
FIGURE 2 | Spot sign and contrast extravasation. Patient admitted
within 2 h after symptom onset. (A) Initial non-contrast CT demonstrating
small basal-ganglia hemorrhage, (B) CTA source image demonstrating
single spot sign (arrow), (C) 3-min post-contrast CT-imaging demonstrating
contrast extravasation (arrow), and (D) 24 h follow-up CT revealing final
hematoma volume.
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to hematoma expansion. Other studies have later supported
this claim, and excellent negative predictive value in predict-
ing hematoma expansion is indicated across studies performed
(Figure 3). The concept of contrast extravasation in general refers
to all manners of contrast-leakage into the hematoma. However,
in more recent studies, the concept of contrast extravasation refers
only to pooling of contrast in the hematoma on post-contrast CT-
imaging following CTA (15). In this review, contrast-leakage will
be used as an umbrella term for both contrast extravasation and
the spot sign.
Wada et al. (16) was the first to describe small enhancing foci
on CTA source images – the spot sign – and its ability to predict
hematoma expansion. Ever since, many other studies have focused
on the spot sign as a promising biomarker to predict hematoma
expansion. Among studies, slightly different definitions of the spot
sign have been used, however, many studies use definitions similar
to the one proposed by Wada et al: “one or more, 1–2 mm foci of
enhancement within the hematoma on CTA source images” or as
proposed by Delgado Almandoz et al. (17): (i) 1≥ focus of contrast
pooling within the ICH; (ii) with an attenuation≥120 Hounsfield
units; (iii) discontinuous from normal or abnormal vasculature
adjacent to the ICH; and (iv) of any size and morphology.
The overall prevalence of the spot sign varies among studies
from 19 to 41% (6, 16–24) (Figure 4). This reflects the differences
FIGURE 3 | Effect of contrast extravasation on hematoma
expansion. This figure presents the predictive values across studies for
contrast extravasation to predict hematoma expansion. The predictive
values indicated the independent effect of contrast extravasation and
not the effect of contrast extravasation in addition to spot sign – please
see text. N CE, number of patients with contrast extravasation; N all,
total number of patients in the population; exp def, definition of
hematoma expansion.
FIGURE 4 | Effect of spot sign on hematoma expansion. This figure presents the predictive values across studies for spot sign in predicting hematoma
expansion. N Sps, number of patients with spot sign; N all, total number of patients in the population; exp def, definition of hematoma expansion.
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in the definition used, different scan protocols and the time-
window utilized. In patients arriving within 3 h, the prevalence
is reported to be as high as 43–60% (6, 17) dropping down to
11% in patients presenting beyond 6 h after onset (6). This is
in good accordance with the proposed temporal profile of post-
admission hematoma expansion, because it indicates that the
majority of expansion happens within the first hours. The spot
sign has been shown to be associated with larger hematoma admis-
sion volume (17, 18, 22, 25), higher admission National Institute
of Health Stroke Scale (NIHSS) value (18), and hypertension on
admission (17, 22). Whether use of vitamin-K antagonists and
antiplatelet medication is associated with a higher prevalence of
the spot sign, varies between study-results (17, 18, 22). It has
been observed that the contrast-phase, in which CTA images were
acquired, plays a role in the prevalence of the spot sign. The preva-
lence of the spot sign was highest in the late venous phase. This
might reflect the time required for contrast to accumulate in the
hematoma (26).
Across studies, the inter-observer agreement for identifying
the spot sign is in general reported to range between good and
moderate (κ= 0.60–0.85) (16, 21, 22). In the PREDICT-study, it
was observed that even though no definition for the spot sign
was selected at the beginning of the study, the agreement in
identifying the spot sign between site-investigators and the final
expert-adjudication was substantial (κ= 0.72) (18). Huynh et al.
(27) presented a study regarding the accuracy of 131 readers to
recognize the spot sign, and it was found that physicians in gen-
eral showed a good specificity (96%), however, the sensitivity
was smaller (78%). This might be due to incorrect perception
of spot sign mimic. The study further shows that the identifi-
cation of spot sign proceeded quickly (27). The spot sign must
consequently be seen as a relatively easily recognizable biomarker.
However, physicians’ ability to recognize it can be improved by
simple learning programs (28). This adds greatly to the every-day
clinical usefulness of the spot sign in acute ICH-patients.
The spot sign has been proven to be a valid biomarker of
hematoma expansion, possibly because of its representation of foci
of active bleeding (29). The spot sign in general yields a relatively
high negative predictive value (NPV: 0.75–0.98) along with slightly
lower positive predictive value (PPV: 0.45–1.00) toward hematoma
expansion (Figure 4) (6, 16–24, 30). Sensitivity and specificity
are reported to be 0.46–0.91 and 0.84–1.00, respectively (6, 16–
24). This is true, even though studies report patients included
in different time intervals after ictus. Brouwers et al. (6) found
that the positive and negative predictive value remained relatively
constant in patients admitted 0–3, 3–6, and >6 h after symptom
onset. This indicates the overall ability of the spot sign to predict
hematoma expansion across various time-windows. Differences
in imaging protocols might also affect the ability of the spot sign
to predict hematoma expansion. Spot sign observed in the peak
arterial contrast-phase might entail a larger absolute hematoma
expansion volume compared to spot sign observed in later venous
phases (26). The effect of the spot sign on hematoma expansion is
observed to be independent from other predictors of hematoma
expansion – especially vitamin-K antagonist use and hematoma
volume (16–18, 22) even through the factors might complement
each other. In a recently proposed prognostic score, time to initial
CT-scan, initial hematoma-size, CTA spot sign, and pre-stroke
warfarin treatment were included in order to enable a better strati-
fication of patients with regard to the likelihood of post-admission
hematoma expansion (31).
Different amendments to the spot sign have been proposed to
increase its ability to identify patients prone to hematoma expan-
sion. Besides the spot sign observed on CTA source images, delayed
post-contrast sequences have been utilized to visualize contrast
extravasation. Two small studies indicate that the presence of both
spot sign and post-contrast extravasation increases the likelihood
of hematoma expansion compared to the spot sign alone (19, 20).
Another related add-on to the spot sign is the so-called tail-sign
(32). The tail-sign is observed originating from the M1 segment
of the middle cerebral artery on coronal CTA images in patients
with a basal-ganglia hemorrhage and is thought to represent active
bleeding from the striate arteries. Only a single smaller study has
elaborated the tail-sign, and additional work is needed to confirm
its validity.
SPOT SIGN SCORE
The spot sign score (SSS) was originally proposed by Delgado
Almandoz et al. (17) in an attempt to systematically characterize
the spot sign and develop a scale capable of predicting hematoma
expansion better than the spot sign per se was able to. The result-
ing SSS is presented in Table 1. In the original study, the score
provided excellent discriminative capability, when it comes to
hematoma expansion (AUC-ROC 0.93 CI: 0.89–0.95), and the risk
of hematoma expansion (>30% or 6 mL) increased from 2% in
the group with a SSS of 0 to 100% in patients with a SSS of four.
Patients with spot sign on admission that arrived in hospital earlier
in general presented with a higher SSS compared to patients, who
arrived later. The authors later demonstrated that the SSS inde-
pendently predicts in-hospital mortality and 3 months outcome
in an almost linear manner (when increasing from SSS 0 to 4, in-
hospital mortality increased from 24 to 75% – and mean 90 days
mRS from 3.2 to mRS 5.4) (33).
Other studies have confirmed the independent capability of SSS
to predict hematoma expansion (21, 23, 34), mortality, and poor
outcome (21, 23) along with the almost linear increase in risk of
poor functional outcome with increasing SSS (23). However, not
all studies have confirmed that SSS contained superior predictive
Table 1 | Spot sign score.
Spot sign characteristics Points
Number of spot signs
1–2 1
≥3 2
Maximal axial dimension
1–4 mm 0
≥5 mm 1
Maximum attenuation
120–179 HU 0
≥180 HU 1
Replicated from Delgado Almandoz et al. (17).
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capabilities of discriminating patients prone to hematoma expan-
sion and poor outcome compared to the spot sign per se (21, 34).
This might suggest that much of the predictive capability of the SSS
is contained within the demonstration of the spot sign. This was
emphasized in a post hoc analysis from the PREDICT-study reveal-
ing no differences between the discriminative capability toward
hematoma expansion of the number of spot signs demonstrated
and the SSS (34). It was further demonstrated that the risk of
hematoma expansion did not increase significantly with increasing
SSS. In contrast to this, the risk of hematoma expansion increased
significantly with increasing number of spot signs present. The
authors speculate that the reason for these differences is that the
attenuation of the spot sign – which was proven to have good
discriminative ability, when it comes to hematoma expansion in
single center studies – might vary between different CT-scanner
manufactures along with differences in contrast administration
protocol (34).
All in all, the SSS would – if proven valid – provide a better pre-
diction of hematoma expansion useful in clinical decision-making
and clinical trials, but so far, the general validity is questionable.
However, due to the relative complexity of obtaining the score
compared to the spot sign per se or number of spot signs, it might
represent a less relevant tool in every-day clinical practice and
outside clinical trials.
RELATIONSHIP BETWEEN CONTRAST-LEAKAGE AND OUTCOME
Both the spot sign and contrast extravasation have been shown to
be associated with poor outcome. The predictive values are pre-
sented in Table 2 for in-hospital mortality, 90 days mortality and
90 days functional outcome.
The presence of contrast-leakage on admission is associated
with short-term clinical outcome (Table 2). It has been shown
that the presence of spot sign on admission CTA is linked to
neurological deterioration within the first 24 h after symptom
onset (18, 35). Across studies, a clear trend toward high neg-
ative predictive values of in-hospital mortality was identified,
however, with relatively modest or poor positive predictive val-
ues (16, 21–23, 33, 36, 37). All in all, the absence of contrast
extravasation or spot sign indicates an overall increased stabil-
ity of the patient during the acute phase of illness. This might
be an important observation, as it appears that the difference in
mortality between spot sign positive and negative patients mani-
fests during the initial days after symptom onset. After the initial
period, the mortality-rate appears to become even between the
two groups (18, 38).
The absence of the spot sign in general is associated with good
negative predictive values, when it comes to 3 months mortality
(18, 21, 22). The spot sign independently increases the probability
of long-term fatality (18, 21, 38) and poor functional outcome
3 months after admission in most studies (21, 23, 33, 38). The
patients with spot sign in general present a higher 3-month modi-
fied Rankin scale score compared to patients without – indicating
poorer functional rehabilitation outcome (18, 38). However, in a
recent prospective study, this association could not be replicated
(22). This finding could represent local variations in treatment
and rehabilitation efforts.
NON-CONTRAST COMPUTED TOMOGRAPHY
Non-contrast computed tomography (NC-CT) remains the radio-
logical investigation of choice conducted, when stroke patients are
admitted for fibrinolysis work-up. Simple and broadly validated
predictors of post-admission hematoma expansion observed on
NC-CT are therefore essential, because this can potentially predict
clinical instability and poor long-term functional outcome.
HEMATOMA-SIZE
For a long period of time, the initial admission hematoma volume
has been recognized as a major determinant of outcome in patients
with acute ICH. In a classic study elaborated by Broderick et al.
(39), it was demonstrated that the 30-day mortality in patients
with basal-ganglia hemorrhage and a volume above 60 mL was as
high as 93% dropping down to 23% for volumes below 30 mL. A
similar pattern was observed for patients with lobar hemorrhages.
Other studies have replicated these findings and added other
measurements of outcome to the predictive capability of the ini-
tial hematoma volume (e.g., in-hospital mortality (40), functional
outcome and mortality (40–44), long-term survival (45)), and ini-
tial hematoma volume features in most clinical grading scores
concerning ICH-patients (46). Hematoma volume and clinical
neurological status score on admission (Glasgow Coma Scale,
NIHSS, or Canadian Stroke Scale) in general compete for being
among the most powerful predictors of outcome.
In the context of acute demonstration of ICH, the natural
questions to be raised are: (1) what volume is the most predic-
tive – the early volume with possible on-going hemorrhage or the
final hematoma volume? (2) Is it safe to assume that a patient, who
arrives early in the hospital and demonstrates a small hematoma
volume, is clinically stable and prone to good outcome? 3) What
can the hematoma volume tell us about the expansion-potential
of the patient?
In an analysis from the VISTA-database (47) on patients pre-
senting with ICH within 6 h after ictus, it was demonstrated that
patients with an initial hematoma volume below 20 mL were sig-
nificantly less likely to undergo hematoma expansion compared to
a hematoma volume above 30 mL (using the 12.5 mL expansion-
definition). The observation that smaller hematomas are more
stable is supported by data from the Recombinant Activated Factor
VII ICH Trial (48, 49) along with other individual publications (50,
51). In addition to a decreased rate of post-admission hematoma
expansion, smaller hematomas are in general associated with a
lower likelihood of early neurological deterioration – and thus a
more stable acute course of illness (35, 47, 52).
In a most interesting study elaborated by Rodriguez-Luna et al.
(35), the hematoma volume was divided by the time from ictus to
admission, yielding an ultra-early hematoma growth pace. It was
demonstrated that a higher growth pace was independently associ-
ated with the occurrence of post-admission hematoma expansion,
early neurological deterioration and poor long-term functional
outcome. The discriminative capability of hematoma growth pace
was better compared to absolute volume on admission toward
early neurological deterioration and poor long-term functional
outcome. This method could potentially solve some of the previ-
ous proposed uncertainties on the predictive value of hematoma
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Table 2 | Effect of contrast-leakage in predicting outcome.
Design Extravasation
sign
No. contrast-leakage
positive (%)
Total number
participating
Time-frame Outcome Sensitivity (%) Specificity (%) PPV (%) NPV (%)
In-hospital mortality
Becker et al. (36) Retrospective Contrast
extravasation
52 (46) 113 All patients Hospital fatality 77 73 63 84
Goldstein et al. (37) Retrospective Contrast
extravasation
58 (56) 104 All patients Hospital fatality 73 50 33 85
Wada et al. (16) Retrospective Spot sign 13 (33) 39 All patients Hospital fatality 43 69 23 85
Delgado Almandoz et al. (33) Retrospective Spot sign 133 (23) 573 All patients Hospital fatality 41 85 56 76
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h Hospital fatality 60 81 20 96
Romero et al. (23) Prospective Spot sign 31 (24) 131 All patients Hospital fatality 68 88 61 91
Rizos et al. (22) Prospective Spot sign 27 (27) 101 Within 6 h Hospital fatality 47 77 26 89
90-days mortality
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h Case fatality 50 82 27 93
Demchuk et al. (18) Prospective Spot sign 53 (25) 211 Within 6 h Case fatality 43 81 43 80
Rizos et al. (22) Prospective Spot sign 27 (27) 101 Within 6 h Case fatality 29 74 26 77
90-days outcome
Delgado-Almandoz et al. (33) Retrospective Spot sign 133 (23) 573 All patients mRS>3a 23 89 51 70
Li and Wang et al. (21) Prospective Spot sign 30 (22) 139 Within 6 h mRS>2 36 94 87 58
Romero et al. (23) Prospective Spot sign 31 (24) 131 Within 24 h mRS>3a 34 94 90 50
Havsteen and Ovesen et al. (38) Prospective Spot sign 37 (29) 128 Within 4.5 h mRS>4 60 86 68 81
aBased on the surviving patients at 3months.
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volumes in patients with early presentation due to possible on-
going hemorrhage, and the method needs validation in broader
populations.
INTRAVENTRICULAR HEMORRHAGIC EXTENSION
Intraventricular hemorrhagic extension is a frequent finding in
patients admitted with acute ICH. In patients admitted earlier than
3 h after symptom onset, intraventricular hemorrhagic extension
(IVH) is present in 31–48% (22, 35, 38, 53, 54), but delayed IVH
can be detected, on follow-up imaging, in up to 20% (53, 54) of
the patients without IVH on admission. This is a consequence of
post-admission hematoma expansion decompressing into the low
resistance ventricular system.
The anatomical location of the intracerebral hematoma is an
important determinant for the probability of IVH. Hematomas
located in the thalamus or the caudate nucleus will more often
extend into the ventricular system due to the proximity (53–57)
compared to lobar hematomas. Hallevi et al. (56) calculated for
each anatomical position a volume range (decompression range),
below which IVH was very unlikely, however, if ICH volume grew
above this range, IVH was very likely. This range was very nar-
row for hematomas located in the thalamus (7.0–12.7 mL) and
pons (4.3–11.2 mL) but considerably wider for lobar hematomas
(15.4–70.7 mL). This implicates that if a patient with thalamic or
pontine hemorrhage without IVH is admitted early after symp-
tom onset or display radiological predictors of active bleeding on
admission CT, later re-scan should be considered due to a high
probability of delayed IVH. The decompression ranges might also
explain the fact that patients with IVH in general present signifi-
cantly higher admission hematoma volumes compared to patients
without (54, 57).
Whether the presence of IVH is associated with hematoma
expansion is controversial. Most studies do not find an association
between hematoma expansion and IVH, however, one study has
shown that lenticular and lobar hematomas with accompanying
IVH displayed a higher proportion of hematoma expansion (54).
This could be explained by the fact that the expansion-potential
is high in a non-periventricular hematoma, if it is able to break
through to the ventricles. This finding needs validation in further
studies.
Intraventricular hemorrhagic extension may be viewed as a
separate hematoma, and expansion of the intraventricular blood
volume can occasionally be observed. Steiner et al. (57) reported
that 12% of patients with initial IVH suffered enlargement of the
IVH volume between baseline and follow-up scan. This expan-
sion was associated with higher baseline ICH hematoma volume,
elevated blood-pressure and short time from symptom onset to
admission scan. Expansion of the IVH volume was independently
associated with poor functional outcome and death.
Intraventricular hemorrhagic extension is reported to be inde-
pendently associated with both early (<48 h after onset) (10, 35,
58) and late (48 h–1 week after onset) (59) neurological dete-
rioration. There is a high load of evidence indicating that the
presence of IVH is independently related to poor clinical out-
come and mortality (43, 45, 60–62) mainly due to the obstruc-
tion of cerebrospinal fluid flow and hydrocephalus (55, 63),
but also by other mechanisms. The association with mortality
and poor outcome is likely related to the severity of the IVH
volume (57, 61, 64).
HEMATOMA HETEROGENICITY (SWIRL-SIGN) AND IRREGULARITY
It is a frequent observation that patients with ICH present
hematomas in various shapes and with heterogeneous attenuation
on NC-CT. It has for a long period of time been a puzzling hypoth-
esis that this could potentially predict the risk of post-admission
hematoma expansion due to the fact that this may signify on-going
bleeding.
The observation that a heterogenic attenuation of the
hematoma on NC-CT represents on-going bleeding originally
descends from observations of patients with epidural hematomas
(65). It was observed that the finding of a zone of hypoattenuation
within the hyperattenuated hematoma – the so-called “Swirl-
sign” – correlated to active bleeding (66). The theory that the
swirl-sign could represent on-going bleeding was founded on early
studies using computed tomography techniques demonstrating
that coagulated and retracted blood-clots appear hyperattenuated
compared to normal brain tissue. When blood coagulates, it expels
low-density serum leaving behind a high concentration of red
blood cells – and thus the globin-protein responsible for the high
attenuation (67). Consequently, if a hematoma contains a mixture
of coagulated (hyperattenuation) and uncoagulated blood (hypo-
or isoattenuation), it appears heterogenic on a NC-CT.
A number of studies have applied the same principle on patients
with acute ICH. Definitions of a heterogeneous attenuation (swirl-
sign) (Figure 5) vary between studies, however, a clinically relevant
and potentially every-day useful definition proposed by Selariu
et al. yielded good intra- and inter-observer agreement: swirl-
sign was defined as regions of hypoattenuation or isoattenuation
(compared to the attenuation of surrounding brain-parenchyma)
within the hyperattenuated ICH (68).
A study elaborated by Barras et al. on patients included on the
placebo arm of the Recombinant Activated Factor VII ICH Trial
reported that hypoattenuated foci on the admission scan indepen-
dently predicted some definitions of hematoma expansion, even
after adjustment for other predictors of hematoma expansion (48).
Additional studies have later confirmed this observation (51, 69).
The presence of heterogeneity is further linked to mortality and
poor functional outcome (68).
It has been shown that patients arriving in the hospital early
have a higher probability of presenting a heterogeneous attenua-
tion of the hematoma. This fits well with the observations of the
timing of post-admission hematoma expansion. In one study, the
prevalence dropped from 36% in patients arriving within 2 h to
13% in patients arriving later that 24 h after symptom onset (68).
The relationship between the swirl-sign and the spot sign would
be of pathophysiological and clinical interest and remains to be
investigated.
Another proposed marker of active bleeding is irregular shape
of the hematoma. The hypothesis behind this observation is that
the irregularity could result from multiple leaking vessels feed-
ing the hematoma and hence a higher probability of hematoma
expansion (70). Even though the observation that irregularity of
the hematoma shape should facilitate hematoma expansion is val-
idated in a large study elaborated by Fujii et al. (71), other studies
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FIGURE 5 | Heterogenicity on admission NC-CT. Admission and follow-up radiology on two patients admitted with acute ICH. NC-CT (A,D) demonstrates
marked heterogenic attenuation in hematoma appearance. Arrow on (D) marks swirl-sign. On (B,E) both patients present spot sign. After 24 h (C,F) both
patients present enlargement of the hematoma volume and midline shift.
have not been able to confirm this finding – thus making irregular
shaping of the hematoma an uncertain predictor of hematoma
expansion (48, 51, 69).
FOLLOW-UP IMAGING IN PATIENTS WITH INTRACEREBRAL
HEMORRHAGE
In relation to the substantial amount of patients undergoing post-
admission hematoma expansion and the trend toward shorter
interval between symptom onset and admission imaging, the
need for follow-up imaging after the acute phase of illness
becomes more crucial (72). In general, follow-up NC-CT 24 h
post-admission is implemented in many centers to evaluate the
final hematoma volume, midline shift, the presence of intraven-
tricular or subarachnoid extension of the hemorrhage, and edema
formation. NC-CT is in general viewed as the gold standard, when
it comes to demonstrating and measuring the volume of ICH.
However, CT is limited by the utility of ionizing radiation making
it unsuitable for serial assessments of the hematoma volume. In
addition, the patients have to leave the stroke wards in most centers
in order to undergo CT-studies.
In recent years, the concept of transcranial duplex sonography
(TCDS) has become available to dynamically follow the progres-
sion of the intracerebral hematoma on B-mode ultrasound images.
The examination is performed through the trans-temporal bone
window (Figure 6). On B-mode images, the hematoma is visu-
alized as a hyperechogenic structure compared to surrounding
brain-parenchyma. The hematoma is often visualized through the
contralateral bone window in reference to the hematoma loca-
tion (73) (Figure 7). The volume of the hematoma is obtained
by measuring the sagittal, transversal, and coronal diameter of the
hematoma and then calculating the volume using the standard
formula: ABC/2 (74, 75) (Figure 7). Studies indicate that TCDS
is able to identify ICH with good sensitivity (73, 75–79). TCDS is
also able to estimate the diameters of the hematoma with system-
atic deviation close to zero (75, 76) and good volume estimation
compared to CT (75–77). Studies further indicate that TCDS is
useful in following hematoma expansion (75) and demonstrating
the presence of IVH (73, 77). In patients with hematomas that are
difficult to visualize on TCDS, the administration of ultrasound
contrast might improve precision of the estimated volume (78).
Midline shift can also dynamically be followed using TCDS by
measuring the distance from the transducer to the third ventri-
cle bilaterally (77, 80, 81). The third ventricle is normally easily
recognized on TCDS (Figure 7). By adding Doppler flow studies
of the intracranial vessels, TCDS might also be able to estimate
intracranial pressure (82, 83), however, additional work needs to
examine this in greater detail.
The major limitation to TCDS in patients with ICH is that not
all patients present with trans-temporal acoustical bone windows
sufficient to allow penetration of diagnostic ultrasound waves. The
proportion of the study populations without an acoustical window
varies from 7 to 56% in studies on ICH-patients, even though most
studies report approximately 20% failure-rate (73, 75, 76, 78, 81,
83). The most notorious predictors of lack of an acoustical window
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are gender (women in general present poorer acoustical windows),
increasing age, and thickness of scull (84, 85). In addition, peo-
ple of Asian descent in general present with a higher prevalence
of inadequate trans-temporal acoustical bone windows compared
FIGURE 6 |Trans-temporal ultrasound window. Approximate location of
the trans-temporal ultrasound window.
to Caucasians (76, 84). TCDS is further limited by the anatomi-
cal location of the hematoma. Volume estimation of hematomas
located either high cortical or infratentorial can be troublesome
due to its position in relation to the trans-temporal bone window
(73, 75, 77).
Even with the presented limitations, evidence suggests the
usefulness of TCDS in patients with ICH as an add-on to the
consecutive clinical surveillance during the acute phase of illness.
CONCLUSION
Post-admission hematoma expansion in patients with ICH con-
tributes to the clinical deterioration, but may also contain an
attractive target for early intervention. CTA for the purpose of
evaluating underlying vascular pathology and presence or absence
of the spot sign should be considered in all acute ICH-patients.
The spot sign has been shown to be a promising biomarker of post-
admission hematoma expansion with good predictive capability.
In patients with contraindications to CTA predictors of on-going
hemorrhage are available for NC-CT. The presence of spot sign,
swirl-sign, IVH, or a large hematoma on admission scan marks
the patient as potentially clinical unstable and as subject for inten-
sified clinical observation and follow-up imaging. Predictors of
hematoma expansion also contain prognostic information toward
long-term functional outcome and mortality. TCDS provides a
new method to consecutively monitor the development of the
hematoma bedside. On-going and future studies will elucidate,
if selection of patients for hemostatic therapy based on radio-
logical predictors of post-admission hematoma expansion will
finally provide us with an effective treatment-offer for patients
with ICH.
FIGURE 7 |Transcranial duplex sonography-images of
basal-ganglia hemorrhage. A patient with basal-ganglia ICH. On axial
images (A,B) the hematoma can be observed as a hyperechogenic
region in the middle of the picture. The rim of the hematoma is marked
by black on (C). In addition on (C) the location of important midline
landmark structures as the pineal gland and the third ventricle are
marked. (D,E) Are coronal images. On (F) the lateral ventricles, the
third ventricle, and the hematoma is marked.
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